Vanguard Group Inc. Has $160.42 Million Stake in Denali Therapeutics Inc. $DNLI

Vanguard Group Inc. decreased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,799,757 shares of the company’s stock after selling 221,473 shares during the period. Vanguard Group Inc. owned 8.12% of Denali Therapeutics worth $160,418,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DNLI. Sterling Capital Management LLC lifted its position in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Denali Therapeutics in the 4th quarter worth $62,000. Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics in the 4th quarter worth $65,000. GAMMA Investing LLC grew its position in Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock worth $108,000 after purchasing an additional 5,705 shares during the last quarter. Finally, Breakwater Capital Group acquired a new stake in Denali Therapeutics in the 1st quarter worth $204,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Activity

In other news, insider Carole Ho sold 2,937 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares in the company, valued at approximately $2,952,169.78. This trade represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander O. Schuth sold 2,937 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider owned 242,346 shares of the company’s stock, valued at approximately $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

DNLI has been the topic of several research analyst reports. William Blair upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. Morgan Stanley dropped their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday. Robert W. Baird dropped their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating for the company in a research note on Thursday, May 8th. HC Wainwright dropped their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Finally, Bank of America dropped their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $33.62.

Denali Therapeutics Stock Down 2.0%

Shares of NASDAQ:DNLI opened at $14.51 on Thursday. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The company’s fifty day moving average is $14.28 and its 200-day moving average is $15.18. The company has a market capitalization of $2.12 billion, a PE ratio of -5.18 and a beta of 1.36.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the company posted ($0.59) earnings per share. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.